An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorosły mężczyzna w wieku 18 lat lub starszy
- •Potwierdzony rак prostaty (potwierdzona wcześniej biopsją)
- •Co najmniej jeden widoczny przerzut nowotworu w obrazowaniu (TK, rezonans lub scyntygrafia kostna)
- •Rak prostaty niezależny od hormonów, który się rozwija mimo terapii
- •Bardzo niska zawartość testosteronu we krwi (castrat level)
- •Wcześniejsze bezskuteczne leczenie za pomocą co najmniej jednego leku z grupy ARPI
- •W zależności od etapu: wcześniejsza chemioterapia możliwa (maksymalnie określona liczba linii)
✗ Disqualifies
- •Wcześniejsze leczenie inhibitorami PRC2 lub podobnymi lekami
- •Wcześniejsze leczenie białkami degradujący ą receptor androgenowy
- •Alergia lub uczulenie na składniki leku
- •Uczestnictwo w innym badaniu klinicznym w ciągu ostatnich 28 dni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 21, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (35)
Sarah Cannon Research Institute
Denver, United States
Sarah Cannon Research Institute
Jacksonville, United States
Emory University
Atlanta, United States
Wichita Urology Group PA
Wichita, United States
Mass General Hospital
Boston, United States
Duke University Medical Center
Durham, United States
Cleveland Clinic Foundation
Cleveland, United States
Fred Hutchinson Cancer Research Center
Seattle, United States
Novartis Investigative Site
St Leonards, Australia
Novartis Investigative Site
Melbourne, Australia
Novartis Investigative Site
Liverpool, Australia
Novartis Investigative Site
Halifax, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Herlev, Denmark
Novartis Investigative Site
Odense C, Denmark
Novartis Investigative Site
Vejle, Denmark
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Düsseldorf, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Padova, Italy
Novartis Investigative Site
Orbassano, Italy
Novartis Investigative Site
Kuching, Malaysia
Novartis Investigative Site
Tlalpan, Mexico
Novartis Investigative Site
Poznan, Poland
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Santiago Compostela, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Sutton, United Kingdom
Novartis Investigative Site
London, United Kingdom
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.